![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 22
Zeitschriftenartikel
Weiss, L.; Heinrich, K.; Zhang, D.; Dorman, K.; Rühlmann, K.; Hasselmann, K.; Klauschen, F.; Kumbrink, J.; Jung, A.; Rudelius, M.; Mock, A.; Ormanns, Steffen 
ORCID: https://orcid.org/0000-0002-0754-9034; Kunz, W. G.; Roessler, D.; Beyer, G.; Corradini, S.; Heinzerling, L.; Haas, M.; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Boeck, S.; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Westphalen, C. B. ORCID: https://orcid.org/0000-0002-5310-3754
(2023):
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 11: S. 8225-8234
[PDF, 623kB]
ORCID: https://orcid.org/0000-0002-0754-9034; Kunz, W. G.; Roessler, D.; Beyer, G.; Corradini, S.; Heinzerling, L.; Haas, M.; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Boeck, S.; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Westphalen, C. B. ORCID: https://orcid.org/0000-0002-5310-3754
(2023):
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 11: S. 8225-8234
[PDF, 623kB]
Kruger, S. F.; Lohneis, A.; Abendroth, A.; Berger, A. W.; Ettrich, T. J.; Waidmann, O.; Kapp, M.; Steiner, B.; Kumbrink, J.; Reischer, A.; Haas, M.; Westphalen, C. B.; Zhang, D.; Miller-Phillips, L.; Burger, P. J.; Kobold, S.; Werner, J.; Subklewe, M.; Bergwelt-Baildon, M. von; Kunzmann, V.; Seufferlein, T.; Siveke, J. T.; Sinn, M.; Heinemann, V.; Ormanns, S. und Boeck, S.
(2022):
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study.
In: ESMO Open, Bd. 7, Nr. 1, 100388
Hartlapp, I.; Valta-Seufzer, D.; Siveke, J. T.; Algul, H.; Goekkurt, E.; Siegler, G.; Martens, U. M.; Waldschmidt, D.; Pelzer, U.; Fuchs, M.; Kullmann, F.; Boeck, S.; Ettrich, T. J.; Held, S.; Keller, R.; Anger, F.; Germer, C. T.; Stang, A.; Kimmel, B.; Heinemann, V. und Kunzmann, V.
(2022):
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113).
In: ESMO Open, Bd. 7, Nr. 4
Haas, M.; Waldschmidt, D. T.; Stahl, M.; Reinacher-Schick, A.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kaiser, F.; Kanzler, S.; Frickhofen, N.; Seufferlein, T.; Dechow, T.; Mahlberg, R.; Malfertheiner, P.; Illerhaus, G.; Kubicka, S.; Abdul-Ahad, A.; Snijder, R.; Kruger, S.; Westphalen, C. B.; Held, S.; Bergwelt-Baildon, M. von; Boeck, S. und Heinemann, V.
(2021):
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
In: European Journal of Cancer, Bd. 146: S. 95-106
Sams, L.; Kruger, S.; Heinemann, V.; Bararia, D.; Haebe, S.; Alig, S.; Haas, M.; Zhang, D.; Westphalen, C. B.; Ormanns, S.; Metzger, P.; Werner, J.; Weigert, O.; von Bergwelt-Baildon, M.; Rataj, F.; Kobold, S. und Boeck, S.
(2021):
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
In: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
[PDF, 1MB]
Ilhan, Harun; Lindner, S.; Todica, A.; Cyran, C. C.; Tiling, R.; Auernhammer, C. J.; Spitzweg, C.; Boeck, S.; Unterrainer, M.; Gildehaus, F. J.; Böning, G.; Jurkschat, K.; Wängler, C.; Wängler, B.; Schirrmacher, R. und Bartenstein, P.
(2020):
Biodistribution and first clinical results of F-18-SiFAlin-TATE PET: a novel F-18-labeled somatostatin analog for imaging of neuroendocrine tumors.
In: European Journal of Nuclear Medicine and Molecular Imaging, Bd. 47, Nr. 4: S. 870-880
Fietkau, R.; Grützmann, R.; Wittel, U. A.; Croner, R. S.; Jacobasch, L.; Neumann, U. P.; Reinacher-Schick, A.; Imhoff, D.; Boeck, S.; Keilholz, L.; Oettle, H.; Hohenberger, W. M.; Golcher, H.; Bechstein, W. O.; Uhl, W.; Pirkl, A.; Adler, W.; Semrau, S.; Rutzner, S.; Ghadimi, M. und Lubgan, D.
(2020):
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007 +/- trial.
In: Strahlentherapie und Onkologie, Bd. 197, Nr. 1: S. 8-18
Rijssen, L. B. van; Veer, E. ter; Besselink, M. G.; Mali, R. M. A.; Berlin, J.; Boeck, S.; Bonnetain, F.; Conroy, T.; Deplanque, G.; Goldstein, D.; Glimelius, B.; Neoptolemos, J. P.; Reni, M.; Scheithauer, W.; Meer, J. van der; Wilmink, J. W.; Poel, M. J. van der; Busch, O. R.; Oijen, M. G. H. van und Laarhoven, H. W. M. van
(2017):
Consensus statement on mandatory measurements in Pancreatic cancer trials for systemic treatment of unresectable disease (COMMPACT).
In: Annals of Oncology, Bd. 28
Quante, A. S.; Ming, C.; Rottmann, Miriam; Engel, Jutta; Boeck, S.; Heinemann, V.; Westphalen, C. B. und Strauch, K.
(2016):
Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030.
In: Cancer Medicine, Bd. 5, Nr. 9: S. 2649-2656
Michl, M.; Haug, A. R.; Jakobs, T. F.; Paprottka, P.; Hoffmann, R. T.; Bartenstein, P.; Boeck, S.; Haas, M.; Laubender, Rüdiger P. und Heinemann, V.
(2014):
Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors.
In: Oncology, Bd. 86, Nr. 1: S. 24-32
Michl, M.; Haug, A. R.; Jakobs, T. F.; Paprottka, Philipp M.; Hoffmann, R.-T.; Bartenstein, P.; Boeck, S.; Haas, M.; Laubender, R. P. und Heinemann, V.
(2014):
Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: Efficacy, safety and prognostic factors.
In: Oncology, Bd. 86, Nr. 1: S. 24-32
[PDF, 265kB]
Boeck, S.; Ormanns, S.; Haas, M.; Bachmann, S.; Laubender, Rüdiger P.; Siveke, J. T.; Jung, A.; Kirchner, T. und Heinemann, V.
(2014):
Translational research in pancreatic cancer: KRAS and beyond.
In: Pancreas, Bd. 43, Nr. 1: S. 150-152
Heinemann, V.; Ebert, M. P.; Laubender, Rüdiger P.; Bevan, P.; Mala, C. und Boeck, S.
(2013):
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.
In: British Journal of Cancer BJC, Bd. 108, Nr. 4: S. 766-770
Haas, M.; Heinemann, V.; Kullmann, F.; Laubender, Rüdiger P.; Klose, C.; Bruns, C. J.; Holdenrieder, S.; Modest, D. P.; Schulz, C. und Boeck, S.
(2013):
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
In: Journal of Cancer Research and Clinical Oncology, Bd. 139, Nr. 4: S. 681-689
Boeck, S.; Jung, A.; Laubender, Rüdiger P.; Neumann, J.; Egg, R.; Goritschan, C.; Vehling-Kaiser, U.; Winkelmann, C.; Fischer von Weikersthal, L.; Clemens, M. R.; Gauler, T. C.; Marten, A.; Klein, S.; Kojouharoff, G.; Barner, M.; Geissler, M.; Greten, T. F.; Mansmann, Ulrich; Kirchner, T. und Heinemann, V.
(2013):
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
In: British Journal of Cancer BJC, Bd. 108, Nr. 2: S. 469-476
Boeck, S.; Jung, A.; Laubender, Rüdiger P.; Neumann, J.; Egg, R.; Goritschan, C.; Ormanns, S.; Haas, M.; Modest, D. P.; Kirchner, T. und Heinemann, V.
(2013):
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.
In: Journal of Gastroenterology, Bd. 48, Nr. 4: S. 544-548
Zeiss, K.; Parhofer, K. G.; Heinemann, V.; Haas, M.; Laubender, Rüdiger P.; Holdenrieder, S.; Schulz, C. und Boeck, S.
(2013):
Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy.
In: Anticancer Research, Bd. 33, Nr. 1: S. 287-292
Haas, M.; Laubender, Rüdiger P.; Klose, C.; Schulz, C.; Mansmann, Ulrich; Boeck, S. und Heinemann, V.
(2012):
External Validation of 2 Prognostic Indices for Patients With Advanced Pancreatic Cancer Treated With First-line Therapy.
In: Pancreas, Bd. 41, Nr. 5: S. 738-744
Modest, D. P.; Jung, A.; Moosmann, N.; Laubender, Rüdiger P.; Giessen, C.; Schulz, C.; Haas, M.; Neumann, J.; Boeck, S.; Kirchner, T.; Heinemann, V. und Stintzing, S.
(2012):
The influence of KRAS- and BRAF-mutations on the efficacy of cetuximab-based 1st-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104 -trial.
In: International Journal of Cancer, Bd. 131, Nr. 4: S. 980-986
Modest, D. P.; Stintzing, S.; Laubender, Rüdiger P.; Neumann, J.; Jung, A.; Giessen, C.; Haas, M.; Aubele, P.; Schulz, C.; Boeck, S.; Stemmler, H. J.; Kirchner, T. und Heinemann, V.
(2011):
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
In: Anticancer Drugs, Bd. 22, Nr. 9: S. 913-918
Haas, M.; Laubender, Rüdiger P.; Stieber, P.; Holdenrieder, S.; Bruns, C. J.; Wilkowski, R.; Mansmann, Ulrich; Heinemann, V. und Boeck, S.
(2010):
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
In: Tumor Biology, Bd. 31, Nr. 4: S. 351-357
Boeck, S.; Haas, M.; Laubender, Rüdiger P.; Kullmann, F.; Klose, C.; Bruns, C. J.; Wilkowski, R.; Stieber, P.; Holdenrieder, S.; Buchner, Hannes; Mansmann, Ulrich und Heinemann, V.
(2010):
Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
In: Clinical Cancer Research, Bd. 16, Nr. 3: S. 986-994